WO2013157984A1 - Препарат и способ профилактики и лечения остеопороза и переломов костей - Google Patents
Препарат и способ профилактики и лечения остеопороза и переломов костей Download PDFInfo
- Publication number
- WO2013157984A1 WO2013157984A1 PCT/RU2012/000689 RU2012000689W WO2013157984A1 WO 2013157984 A1 WO2013157984 A1 WO 2013157984A1 RU 2012000689 W RU2012000689 W RU 2012000689W WO 2013157984 A1 WO2013157984 A1 WO 2013157984A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoporosis
- treatment
- vitamin
- per day
- drone brood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Definitions
- the invention relates to medicine, in particular to means for therapeutic and prophylactic effects in conditions associated with various forms of osteoporosis.
- Osteoporosis is a metabolic disease of the skeleton, characterized by a decrease in bone mass per unit volume and a violation of the microarchitectonics of bone tissue, leading to a decrease in the amount of calcium in the bones and a high risk of fractures of any bones, including the femoral neck.
- the closest analogue to our invention is a biologically active food supplement for the prevention of osteoporosis (Osteomed drug, consisting of calcium, drone brood in various proportions, patent for invention 2412616, A23L1 / 30, 2009).
- Vitamin or vitamins of group D from 50 ME to 1 000 000 ME LLC per day.
- the claimed tool can be made in tablet, powder or capsule form and is divided into one or more doses in a daily dose.
- the technical result is to eliminate or reduce the imbalance in the mineralization of various sections of bone tissue.
- the use of the claimed agent enhances the mechanism of uniform restoration of bone mineral density, the use of drone brood together with vitamin D is aimed at additional strengthening of remodeling of affected areas of bone tissue, and bone retention by maintaining the level of androgens.
- the method involves taking drone brood from 10 mg to 1000 mg per day, vitamin or vitamins of group D, and / or their active metabolites from 50 ME to 1000 000 ME per day a calcium compound of 25 mg to 3,000 mg per day; and a preparation for the prevention and treatment of osteoporosis and bone fractures, consisting of drone brood from 10 mg to 1000 mg, vitamin or vitamins of group D, and / or their active metabolites 50 ME to 1000 000 ME, calcium compounds from 25 mg to 3000 mg, according to the invention, the drone brood, vitamin or vitamins of group D, and / or their active metabolites, calcium compound enter the body simultaneously during the day, in powder, tablet or capsule form.
- a method for the prevention and treatment of osteoporosis and bone fractures is as follows.
- Example 1 We conducted a study of the comparative effectiveness of "osteomed” and the claimed drug in 56 patients with postmenopausal osteoporosis. Depending on the method of treatment, 56 women aged 47 to 72 years with postmenopausal (primary) osteoporosis were divided into two groups of diseases comparable in age and severity:
- Group 2 (29 women) received CPF of 5 tablets (2 in the morning and 3 at night).
- Example.2 As an example of the effectiveness of the claimed means of treating osteoporosis of CPPL in comparison with the drug Calcium D3 Nycomed, we give the following observation.
- Fig. 1 Abdominal masses before treatment with the claimed agent.
- Example. C closure of cavities using the inventive means for the treatment of osteoporosis.
- the breadth of the range of the claimed drug is explained by the individual characteristics of the patient: his age, diet, lifestyle, race, country of residence, gender, hereditary and transferred diseases.
- the doctor evaluating these criteria, selects an individual proportion of the components of the claimed drug and adjusts it based on the dynamics of the closure of the cavity formations.
- the weight of the patient affects the dosage of the drug. Thin women with white skin are more likely to osteoporosis than swarthy and full. In overweight women, adipose tissue produces estrogens that prevent the formation of osteoporosis. In obese women, osteoporosis is rarely diagnosed. Therefore, the fuller the woman, the lower the dosage.
- Vitamin or vitamins of group D (and / or their active metabolites) from 50 ME to 1 000 000 ME LLC per day.
- the lower limit is due to the effective dose, and the upper limit is due to toxicity.
- Drone brood from 10 mg to 1000 mg per day The lower limit is explained by the effective dose, and the upper limit is explained by the appropriateness of application in terms of proportion: the effectiveness / appreciation of the product.
- vitamin D The introduction of vitamin D is explained by the fact that the drone brood is saturated with vitamins, but in unsubstituted, small doses, in particular with vitamin DZ. Therefore, its concentration is extremely insufficient for the treatment of osteoporosis.
- Drone brood serves as a substrate for the synthesis of their own sex hormones (estradiol, testosterone), which have a stimulating effect on the reproductive functions of men and women. Saturated with hormones of beneficial insects (bee drones), brood stimulates the central mechanisms of regulation of reproductive organs and eliminates the need for replacement therapy. Only a complex of these drugs can improve the absorption of Ca and its deposition in areas of bones with low mineralization, the so-called cavity formations. This is confirmed by the results of x-ray osteometry.
- the use of the claimed drug enhances the mechanism of calcium replenishment in the body, because the use of calcium compounds with vitamin D is aimed at the additional supply of Ca, while the simultaneous use of drone brood contributes to its retention by maintaining the level of androgens.
- the combined use of vitamin D with calcium and drone brood will achieve the greatest effectiveness in the treatment of osteoporosis, reduce the incidence of side complications in the form of calcifications and stone formation in the kidneys.
- the dynamics of the effectiveness of the proposed tool in comparison with the prototype can be demonstrated in the following examples.
- FIG. 8 - A snapshot before the prototype treatment.
- Fig. 9 Decrease in cavity formations after 9 months of prototype treatment in patient T.
- JVs2 example.
- Patient AA 70 years old, postmenopausal osteoporosis.
- the dosage of its constituent parts is selected by the doctor individually, based on the patient’s disease state and the negative effect of vitamin D and large doses of calcium on the body as a whole. It is proposed to evaluate the patient’s condition using densitometry devices - measuring cavity formations every 6-9 months, and making adjustments to the composition of the claimed means.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Insects & Arthropods (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015506935A JP6286418B2 (ja) | 2012-04-19 | 2012-08-21 | 骨粗鬆症もしくは骨折の予防または治療剤 |
UAA201412409A UA111280C2 (uk) | 2012-04-19 | 2012-08-21 | Препарат та спосіб для профілактики і лікування остеопорозу та переломів кісток |
BR112014025973-9A BR112014025973B1 (pt) | 2012-04-19 | 2012-08-21 | Preparação e método para prevenir e tratar a osteoporose e fraturas ósseas |
CA2870828A CA2870828C (en) | 2012-04-19 | 2012-08-21 | A method for preventing and treating osteoporosis and bone fractures and a preparation for preventing and treating osteoporosis and bone fractures |
EP12874726.8A EP2875820A4 (en) | 2012-04-19 | 2012-08-21 | COMPOSITION AND METHOD FOR PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS AND BONE BREAKS |
CN201280074010.9A CN104379154A (zh) | 2012-04-19 | 2012-08-21 | 骨折和骨质疏松防治方法和药物 |
US14/395,482 US20150174176A1 (en) | 2012-04-19 | 2012-08-21 | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures |
AU2012377478A AU2012377478B2 (en) | 2012-04-19 | 2012-08-21 | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures |
EA201401157A EA026534B1 (ru) | 2012-04-19 | 2012-08-21 | Препарат и способ профилактики и лечения остеопороза и переломов костей |
IL235171A IL235171B (en) | 2012-04-19 | 2014-10-19 | A method for preventing and treating osteoporosis and bone fractures and a preparation for preventing and treating osteoporosis and bone fractures |
IN9779DEN2014 IN2014DN09779A (ru) | 2012-04-19 | 2014-11-19 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012115653 | 2012-04-19 | ||
RU2012115653/15A RU2498811C1 (ru) | 2012-04-19 | 2012-04-19 | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013157984A1 true WO2013157984A1 (ru) | 2013-10-24 |
Family
ID=49383802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2012/000689 WO2013157984A1 (ru) | 2012-04-19 | 2012-08-21 | Препарат и способ профилактики и лечения остеопороза и переломов костей |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150174176A1 (ru) |
EP (1) | EP2875820A4 (ru) |
JP (1) | JP6286418B2 (ru) |
CN (1) | CN104379154A (ru) |
AU (1) | AU2012377478B2 (ru) |
BR (1) | BR112014025973B1 (ru) |
CA (1) | CA2870828C (ru) |
EA (1) | EA026534B1 (ru) |
IL (1) | IL235171B (ru) |
IN (1) | IN2014DN09779A (ru) |
RU (1) | RU2498811C1 (ru) |
UA (1) | UA111280C2 (ru) |
WO (1) | WO2013157984A1 (ru) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105050607A (zh) * | 2013-01-11 | 2015-11-11 | 帕拉法姆有限责任公司 | 用于治疗关节炎和骨关节炎的方法和组合物 |
CN105101980A (zh) * | 2013-01-11 | 2015-11-25 | 帕拉法姆有限责任公司 | 用于加快骨折愈合的方法和组合物 |
US20160136208A1 (en) * | 2013-07-03 | 2016-05-19 | Obshchestvo s ogranichennoj otvetstvennost'ju <“>Parafarm<”> | Application of adsorbed drone brood homogenate and of vitamin d3 or d-group vitamins and/or active metabolites thereof for preventing and treating viral diseases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2593018C1 (ru) * | 2015-10-28 | 2016-07-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ лечения остеоартроза |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2412616C1 (ru) | 2009-11-30 | 2011-02-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики заболеваний остеопорозом |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743596A (en) * | 1987-06-16 | 1988-05-10 | Lapin Alfred R | Anti-arthritic preparation |
CN1101684C (zh) * | 1997-07-24 | 2003-02-19 | 薛大权 | 蜂蛹钙制剂 |
WO2002013832A1 (fr) * | 2000-08-17 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Agent therapeutique destine au traitement de l'osteoporose |
MXPA05013115A (es) * | 2003-06-06 | 2006-05-25 | Wyeth Corp | Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos. |
EA018580B1 (ru) * | 2008-02-13 | 2013-09-30 | ДСМ АйПи АССЕТС Б.В. | Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза |
FR2945748A1 (fr) * | 2009-05-20 | 2010-11-26 | Debregeas Et Associes Pharma | Medicament a base de calcium et de vitamine d. |
RU2497533C1 (ru) * | 2012-04-19 | 2013-11-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для профилактики и лечения атипичного остеопороза с нормальной или повышенной минерализацией костной ткани с наличием полостных образований в трабекулярных отделах костей (и ему близких состояниях при избыточной массе и метаболическом синдроме) |
-
2012
- 2012-04-19 RU RU2012115653/15A patent/RU2498811C1/ru active
- 2012-08-21 EA EA201401157A patent/EA026534B1/ru unknown
- 2012-08-21 AU AU2012377478A patent/AU2012377478B2/en active Active
- 2012-08-21 JP JP2015506935A patent/JP6286418B2/ja not_active Expired - Fee Related
- 2012-08-21 EP EP12874726.8A patent/EP2875820A4/en active Pending
- 2012-08-21 BR BR112014025973-9A patent/BR112014025973B1/pt active IP Right Grant
- 2012-08-21 US US14/395,482 patent/US20150174176A1/en active Pending
- 2012-08-21 CA CA2870828A patent/CA2870828C/en active Active
- 2012-08-21 WO PCT/RU2012/000689 patent/WO2013157984A1/ru active Application Filing
- 2012-08-21 CN CN201280074010.9A patent/CN104379154A/zh active Pending
- 2012-08-21 UA UAA201412409A patent/UA111280C2/uk unknown
-
2014
- 2014-10-19 IL IL235171A patent/IL235171B/en active IP Right Grant
- 2014-11-19 IN IN9779DEN2014 patent/IN2014DN09779A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2412616C1 (ru) | 2009-11-30 | 2011-02-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики заболеваний остеопорозом |
Non-Patent Citations (4)
Title |
---|
"Kaltsy, vitamin D and his metabolity v lechenii osteoporoza.", 2 January 2010 (2010-01-02), pages 1, XP055174226, Retrieved from the Internet <URL:http://www.scientificmedicine.ru/revmatolog/Kalcijj-vitamin-D> [retrieved on 20121226] * |
"Kaltsy-DZ Nikomed forte.", 29 December 2006 (2006-12-29), pages 1 - 2, XP055173911, Retrieved from the Internet <URL:http://www.poisklekarstv.ru/lekcat/2533_kaltsiyd3-nikomed-forte.html> [retrieved on 20121226] * |
"Osteomed.", 2010, pages 1, XP055173919, Retrieved from the Internet <URL:http://www.ortho.ru/agents/min/sz_osteomed.html> [retrieved on 20121226] * |
See also references of EP2875820A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105050607A (zh) * | 2013-01-11 | 2015-11-11 | 帕拉法姆有限责任公司 | 用于治疗关节炎和骨关节炎的方法和组合物 |
CN105101980A (zh) * | 2013-01-11 | 2015-11-25 | 帕拉法姆有限责任公司 | 用于加快骨折愈合的方法和组合物 |
EP2944315A4 (en) * | 2013-01-11 | 2016-07-20 | Obshestvo S Ogranichennoj Otvetstvennostju Parafarm | METHOD AND PRODUCT FOR ACCELERATING CONSOLIDATION OF BONE FRACTURES |
US20160136208A1 (en) * | 2013-07-03 | 2016-05-19 | Obshchestvo s ogranichennoj otvetstvennost'ju <“>Parafarm<”> | Application of adsorbed drone brood homogenate and of vitamin d3 or d-group vitamins and/or active metabolites thereof for preventing and treating viral diseases |
Also Published As
Publication number | Publication date |
---|---|
UA111280C2 (uk) | 2016-04-11 |
RU2498811C1 (ru) | 2013-11-20 |
EP2875820A4 (en) | 2016-01-27 |
BR112014025973B1 (pt) | 2021-09-28 |
CN104379154A (zh) | 2015-02-25 |
AU2012377478B2 (en) | 2017-07-06 |
AU2012377478A8 (en) | 2014-12-18 |
IL235171B (en) | 2019-09-26 |
US20150174176A1 (en) | 2015-06-25 |
EA201401157A1 (ru) | 2015-05-29 |
JP6286418B2 (ja) | 2018-02-28 |
IL235171A0 (en) | 2014-12-31 |
JP2015514755A (ja) | 2015-05-21 |
CA2870828C (en) | 2019-01-15 |
EA026534B1 (ru) | 2017-04-28 |
EP2875820A1 (en) | 2015-05-27 |
CA2870828A1 (en) | 2013-10-24 |
BR112014025973A2 (pt) | 2017-06-27 |
AU2012377478A1 (en) | 2014-12-11 |
IN2014DN09779A (ru) | 2015-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2412616C1 (ru) | Биологически активная добавка к пище для профилактики заболеваний остеопорозом | |
US20110028439A1 (en) | Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer | |
RU2498811C1 (ru) | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей | |
CA2870823C (en) | A method for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralizarion with the presence of cavities in trabecular sections of bone (and conditions similar thereto involving excess mass and metabolic syndrome) | |
CN105816469B (zh) | 20(R)-人参皂苷Rg3在制备用于治疗骨质疏松症的药物或保健品中的应用及药物 | |
CN103349674B (zh) | 一种增加骨密度、防治骨质疏松症的龟甲林蛙油组合物 | |
Ahtamovna | Hypoparathyroidism | |
JP2015516974A5 (ja) | 骨の線維柱帯における空洞病巣発生を有する正常又は増加した骨組織石灰化に伴う非定型骨粗鬆症を対象にする予防または治療剤 | |
BR112017007364B1 (pt) | Composições farmacêuticas e usos das mesmas para o tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes submetidos à cirurgia de bypass gástrico | |
WO2012166003A1 (ru) | Способ заполнения кальцием полостных образований костей | |
EA028560B1 (ru) | Способ и препарат для лечения артритов и артрозов | |
WO2015002576A1 (ru) | Применение адсорбированного гомогената трутневого расплода и витамина d3 или витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний | |
EA028547B1 (ru) | Применение трутневого расплода с соединением кальция для лечения артритов и артрозов | |
US20190381072A1 (en) | Preparation for the Prophylaxis and Treatment of Atypical Osteoporosis | |
CN105101980B (zh) | 用于加快骨折愈合的方法和组合物 | |
RU2555351C1 (ru) | Способ лечения хронического описторхоза у больных с розацеа | |
UA50462A (ru) | Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением | |
WO2012128672A2 (ru) | Биологически активная добавка к пище для профилактики эректильной дисфункции у мужчин | |
CN103463170A (zh) | 一种用于治疗骨质增生的中药有效部位组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12874726 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2870828 Country of ref document: CA Ref document number: 2015506935 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201412409 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201401157 Country of ref document: EA Ref document number: 2012874726 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014025973 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2012377478 Country of ref document: AU Date of ref document: 20120821 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14395482 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014025973 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141017 |